porcin
hemagglutin
encephalomyel
phe
caus
coronaviru
hemagglutin
encephalomyel
viru
phecov
recent
rapid
spread
phecov
piglet
mani
countri
emphas
urgent
need
phecov
vaccin
use
murin
model
evalu
induct
humor
cellular
immun
respons
inactiv
phecov
dna
vaccin
order
defin
immun
correl
protect
phecov
inactiv
vaccin
compos
purifi
phecov
aluminum
hydroxid
gel
alum
chosen
adjuv
long
histori
safeti
human
use
phecov
dna
vaccin
construct
subclon
gene
phecov
vector
creat
recombin
plasmid
result
show
inactiv
phecov
vaccin
ipv
elicit
high
level
humor
immun
result
good
protect
efficaci
phecov
challeng
ipv
induc
subclass
serum
antibodi
express
cytokin
suggest
ipv
gener
predominantli
immun
respons
dna
vaccin
found
mediat
primarili
cellular
immun
respons
high
level
cytokin
gamma
interferon
howev
mice
vaccin
twice
dna
vaccin
boost
ipv
could
mount
suffici
neutral
antibodi
respons
live
phecov
littl
variat
level
show
high
level
respons
may
activ
b
cell
mount
specif
humor
cellular
immun
respons
could
turn
elicit
phagocytemedi
defens
phecov
infect
achiev
viral
clearanc
p
orcin
hemagglutin
encephalomyel
phe
acut
highli
contagi
diseas
piglet
caus
coronaviru
hemagglutin
encephalomyel
viru
phecov
member
coronavirida
famili
phecov
infect
mainli
piglet
age
week
caus
vomit
exhaust
obviou
neurolog
symptom
mortal
rate
rang
pathogen
isol
first
time
vivo
breastfeed
pig
suffer
encephalomyel
canada
antigen
ident
viru
isol
england
suckl
pig
show
anorexia
depress
vomit
clear
sign
encephalomyel
anim
die
stunt
growth
thu
condit
call
vomit
wast
diseas
vwd
mengel
cutlip
later
abl
reproduc
form
diseas
experiment
use
field
isol
phe
report
major
pigproduc
countri
europ
asia
north
america
appear
endem
clinic
outbreak
phecov
first
report
china
eventu
occur
mainland
taiwan
provinc
studi
chemic
composit
phecov
reveal
rna
viru
five
polypeptid
four
whichth
nucleocapsid
n
membran
spike
hemagglutininesteras
proteinsar
glycosyl
coronaviru
glycoprotein
major
determin
neurovirul
respons
viral
attach
cellular
receptor
fusion
viral
cellular
membran
result
viru
entri
glycoprotein
also
induc
neutral
antibodi
vivo
vitro
well
cellmedi
immun
mani
viral
antigen
includ
transgen
plant
demonstr
effect
induc
mucos
serum
immun
respons
anim
natur
host
phecov
pig
viru
adapt
experiment
replic
mice
wistar
rat
viru
neurotrop
mice
suscept
found
influenc
age
rout
inocul
experiment
condit
diseas
reproduc
instanc
follow
oronas
exposur
nonimmun
pig
phecov
first
week
life
clinic
sign
may
vari
howev
studi
virul
sever
phecov
field
isol
compar
symptom
sever
relat
differ
host
suscept
appar
virul
isol
contrast
older
pig
neonat
pig
receiv
antibodi
colostrum
usual
clinic
unaffect
expos
phecov
otherwis
similar
condit
thu
neonat
pig
usual
protect
passiv
acquir
colostr
antibodi
subsequ
develop
agerel
resist
potenti
clinic
effect
viru
recent
incid
phe
among
pig
mani
countri
found
rise
result
great
econom
loss
pig
industri
august
pig
farm
argentina
experienc
outbreak
phe
lead
death
morbid
rate
high
mortal
rate
phe
outbreak
occur
twice
pig
farm
jilin
provinc
incid
rate
among
piglet
high
report
mortal
rate
remark
recent
viru
isol
show
high
degre
genet
antigen
homolog
refer
strain
thu
pig
industri
ignor
potenti
hazard
phe
develop
phecov
vaccin
control
phecov
infect
econom
medic
signific
follow
establish
vaccin
protocol
one
best
way
shorten
time
minim
cost
new
vaccin
develop
current
development
method
inactiv
vaccin
well
establish
vaccin
exhibit
good
immunogen
high
stabil
high
secur
eas
storag
benefit
dna
vaccin
technolog
howev
rel
new
seek
use
gene
therapi
express
protect
immun
insert
origin
gene
cell
produc
antigen
endogen
protein
express
express
protein
present
immun
system
caus
longterm
sustain
antibodi
respons
cytotox
tlymphocyt
ctl
base
cell
immun
studi
cdna
phecov
gene
direct
subclon
vector
downstream
cytomegaloviru
cmv
promot
creat
recombin
gene
dna
vaccin
plasmid
time
phecov
inactiv
use
formaldehyd
appropri
amount
alum
ad
produc
inactiv
phecov
vaccin
determin
immunogen
inactiv
phecov
phecov
dna
vaccin
candid
immun
mice
intramuscularli
candid
vaccin
assess
efficaci
humor
cellular
immun
respons
elicit
phecov
infect
murin
model
viru
strain
viru
strain
use
studi
genbank
access
virus
propag
passag
porcin
kidney
epitheli
cell
cell
purifi
sucros
densiti
gradient
centrifug
store
use
prepar
inactiv
phecov
vaccin
purifi
phecov
inactiv
formaldehyd
describ
previous
inactiv
viru
dilut
phosphatebuff
salin
pb
mix
alhydrogel
dilut
accord
refer
protocol
veterinari
biolog
product
qualiti
standard
china
http
wwwmoagovcnzwllmzcfg
yield
final
concentr
gml
viru
mgml
alum
inactiv
phecov
vaccin
ipv
store
use
prepar
phecov
dna
vaccin
gene
amplifi
phecov
genom
rna
subclon
vector
invitrogen
carlsbad
ca
construct
recombin
plasmid
phecov
purifi
sucros
densiti
gradient
centrifug
viral
rna
extract
use
trizol
reagent
invitrogen
carlsbad
ca
gene
amplifi
use
follow
oligonucleotid
primer
forward
revers
revers
transcriptionpcr
rtpcr
perform
total
reaction
volum
l
use
onestep
rtpcr
kit
takara
dalian
china
revers
transcript
perform
h
pcr
perform
initi
denatur
min
follow
cycl
min
final
extens
min
pcr
product
purifi
clone
vector
creat
plasmid
gene
fragment
recov
doubleenzym
cleavag
use
ecori
noti
direct
subclon
downstream
cmv
promot
creat
construct
accuraci
construct
confirm
restrict
enzym
digest
sequenc
plasmid
purifi
use
gene
jet
plasmid
miniprep
kit
mbi
fermenta
suspend
trisedta
te
buffer
final
concentr
mgml
recombin
strain
screen
pcr
express
product
identifi
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
western
blot
analysi
fig
result
demonstr
presenc
protein
confirm
success
construct
recombin
plasmid
phecov
dna
vaccin
store
use
mice
immun
femal
balbc
mice
week
old
purchas
depart
laboratori
anim
gener
hospit
shenyang
militari
region
anim
maintain
pathogenfre
condit
randomli
divid
two
group
group
consist
mice
per
vaccin
group
immun
week
sacrif
week
examin
humor
cellmedi
immun
respons
result
immun
differ
phecov
vaccin
mice
immun
intramuscularli
either
ml
inactiv
phecov
ip
ii
ml
ipv
iii
ml
pb
neg
control
iv
g
v
ml
ipv
week
g
week
ipv
vi
g
week
ipv
week
ipv
vii
g
group
consist
mice
per
vaccin
group
immun
describ
subsequ
challeng
live
phecov
week
vn
assay
viru
neutral
vn
assay
reliabl
measur
hemagglutin
inhibit
hi
test
detect
phecov
infect
serum
vn
assay
inactiv
min
dilut
minimum
essenti
medium
mem
twofold
dilut
heatinactiv
serum
test
presenc
antibodi
would
neutral
infect
tissu
cultur
infect
dose
tcid
phecov
cell
monolay
serum
dilut
complet
inhibit
cytopath
effect
cpe
well
calcul
describ
previous
determin
antigenspecif
antibodi
subclass
use
elisa
enzymelink
immunosorb
assay
elisa
use
determin
subclass
serum
antiphecov
antibodi
week
use
previous
describ
method
modif
gene
amplifi
phecov
genom
rna
subclon
construct
recombin
plasmid
express
product
analyz
western
blot
analysi
lane
pagerul
prestain
protein
ladder
lane
recombin
plasmid
lane
plasmid
briefli
purifi
phecov
dilut
carbon
buffer
ph
final
concentr
gml
volum
lwell
use
coat
polystyren
microtit
plate
incub
overnight
h
plate
wash
three
time
pbstween
pbst
nonspecif
bind
site
block
lwell
wtvol
bovin
serum
albumin
bsa
h
plate
wash
three
time
l
serum
l
pb
contain
bsa
ad
well
plate
incub
h
detect
serum
subclass
antimous
iga
antibodi
sigma
ad
well
plate
incub
h
three
wash
pbst
plate
incub
peroxidaseconjug
antimous
igg
antibodi
sigma
four
wash
pbst
l
well
ophenylenediamin
opd
ad
color
develop
plate
incub
dark
reaction
stop
addit
h
solut
absorb
well
nm
measur
use
univers
micropl
reader
cellular
immun
respons
two
phecov
candid
vaccin
lymphocyt
transform
assay
use
detect
cellular
immun
respons
immun
mice
elicit
differ
phecov
vaccin
singlecel
suspens
splenocyt
immun
mice
prepar
mice
kill
cervic
disloc
spleen
harvest
disrupt
splenocyt
ad
ml
rpmi
gibco
invitrogen
corpor
centrifug
g
min
cell
suspend
rpmi
supplement
fetal
calf
serum
fc
concentr
cellsml
cell
suspens
l
ad
cell
cultur
plate
american
costar
treat
concanavalin
cona
gml
inactiv
phecov
final
concentr
gml
l
rpmi
use
control
assay
repeat
time
serum
plate
incub
co
h
l
bromid
mtt
mgml
ad
well
plate
incub
anoth
h
final
l
dimethyl
sulfoxid
dmso
ad
well
plate
incub
dark
room
temperatur
min
optic
densiti
nm
od
measur
use
univers
micropl
reader
region
tcell
respons
two
phecov
candid
vaccin
splenocyt
suspens
prepar
describ
cell
dilut
pb
concentr
ml
aliquot
ad
fluorescein
isothiocyan
fitc
conjug
antimous
phycoerythrin
pe
antimous
peconjug
antimous
antibodi
biolegend
san
diego
ca
cell
mixtur
incub
ice
min
wash
twice
pb
ph
centrifug
g
min
suspend
l
pb
follow
detect
use
flow
cytometri
enzymelink
immunosorb
spot
elispot
assay
three
mice
per
treatment
sacrif
spleen
collect
singlecel
suspens
stimul
inactiv
phecov
prepar
level
cytokin
tumor
necrosi
factor
alpha
gamma
interferon
detect
use
elisa
kit
r
accord
manufactur
instruct
cell
cultur
supernat
dilut
microtit
plate
l
biotinlabel
antibodi
ad
plate
incub
min
wash
solut
lwell
ad
min
plate
wash
time
avidinhorseradish
peroxidas
hrp
label
antibodi
lwell
ad
plate
first
incub
min
wash
time
final
lwell
color
reagent
tetramethyl
benzidin
tmb
ad
plate
incub
dark
min
reaction
stop
addit
stop
solut
absorb
well
nm
measur
use
univers
micropl
reader
statist
analysi
data
present
mean
immun
mice
group
standard
deviat
sd
spss
version
window
use
statist
analysi
differ
humor
cellular
immun
respons
group
analyz
use
oneway
analysi
varianc
leastsignificantdiffer
test
use
betweengroup
comparison
p
valu
consid
statist
signific
blood
sampl
obtain
tail
vein
group
mice
week
sera
collect
centrifug
sera
use
vn
detect
fig
contrast
pb
control
group
mice
vaccin
differ
phecov
vaccin
demonstr
detect
serum
neutral
antibodi
titer
week
vn
titer
highest
three
immun
ipv
addit
alum
ipv
prepar
increas
serum
neutral
antibodi
level
significantli
immun
protocol
p
mice
immun
ipv
show
similar
serum
neutral
antibodi
titer
p
titer
ipv
higher
ipv
serum
neutral
antibodi
respons
could
detect
within
period
mice
immun
either
pb
control
subclass
serum
antibodi
elicit
immun
differ
phecov
vaccin
subclass
serum
antiphecov
antibodi
individu
sera
collect
week
detect
elisa
use
antimous
iga
secondari
antibodi
fig
interestingli
level
antiphecov
mice
immun
ipv
compar
mice
immun
virion
alon
wherea
level
antiphecov
higher
mice
immun
ipv
mice
immun
ip
without
alum
p
contrast
level
significantli
higher
ipv
group
ipv
group
show
littl
variat
high
level
detect
notabl
obtain
tail
vein
group
mice
week
sera
use
detect
vn
antibodi
titer
express
log
n
calcul
use
method
reed
muench
vn
titer
determin
week
postimmun
indic
signific
differ
among
ipv
ipv
group
p
howev
among
immun
vaccin
group
vn
titer
significantli
higher
ipv
group
group
ip
ipv
ipv
p
level
iga
antibodi
low
sera
mice
immun
differ
phecov
vaccin
protect
efficaci
phecov
vaccin
challeng
phecov
assess
efficaci
differ
phecov
vaccin
group
mice
immun
subsequ
challeng
live
phecov
week
vaccin
period
time
phecov
challeng
mice
appear
normal
activ
appetit
show
sign
advers
reaction
vaccin
administr
site
brain
sampl
collect
mice
deepli
anesthet
kill
week
challeng
collect
tissu
weigh
homogen
volum
pb
tissu
suspens
centrifug
rpm
min
supernat
use
rna
extract
rtpcr
result
shown
tabl
viral
rna
undetect
brain
homogen
anim
vaccin
ipv
ipv
indic
two
vaccin
could
effect
reduc
infect
death
rate
mice
interestingli
phecov
rna
still
detect
brain
homogen
mice
vaccin
ipv
even
though
protect
effect
ipv
pb
control
group
phecov
rna
detect
brain
homogen
vaccin
mice
die
day
intranas
challeng
live
phecov
examin
whether
vaccin
mice
mount
tcell
respons
phecov
mtt
chronometri
lymphocyt
prolifer
assay
use
splenocyt
immun
mice
stimul
phecov
specif
antigen
cona
nonspecif
antigen
repres
result
prolifer
studi
shown
fig
compar
background
od
od
posit
control
mice
immun
inactiv
phecov
plu
alum
ipv
group
mount
stronger
prolifer
respons
mice
immun
inactiv
phecov
ip
group
p
indic
addit
alum
enhanc
cellular
immun
respons
howev
od
valu
ipv
group
slightli
higher
ipv
group
p
obviou
differ
od
valu
ipv
group
group
p
activ
lymphocyt
among
crucial
antivir
effector
character
tcell
respons
use
flow
cytometri
examin
splenocyt
collect
immun
mice
percentag
cell
mice
immun
ipv
inactiv
phecov
plu
alum
ip
inactiv
phecov
alon
ipv
plasmid
inactiv
phecov
plu
alum
ipv
inactiv
phecov
plu
alum
plasmid
increas
significantli
mice
immun
either
pb
control
p
percentag
cell
howev
obvious
differ
differ
immun
group
p
fig
percentag
activ
cell
ipv
group
slightli
higher
ip
group
p
indic
alum
enhanc
specif
memori
tcell
respons
percentag
activ
cell
ipv
group
slightli
higher
ipv
group
p
ratio
cell
fig
mice
immun
vaccin
higher
control
group
result
indic
differ
immun
protocol
capabl
induc
activ
tcell
immun
respons
mice
assess
product
cytokin
elicit
two
phecov
vaccin
candid
frequenc
cell
produc
singlecel
level
determin
use
elispot
assay
shown
fig
ipv
could
induc
product
four
cytokin
test
mice
control
group
exhibit
low
number
nonspecif
spot
howev
ipv
group
produc
mainli
level
higher
ip
group
ipv
group
show
higher
level
group
high
level
level
show
littl
differ
group
except
control
group
ipv
group
higher
level
ipv
group
ipv
may
produc
immun
respons
may
elicit
phagocytemedi
defens
phecov
infect
involv
clearanc
viru
pig
speci
known
natur
suscept
phecov
infect
infect
speci
subclin
overal
econom
impact
diseas
low
serolog
survey
reveal
infect
swine
phecov
common
probabl
worldwid
occurr
fatten
pig
sera
test
canada
northern
ireland
england
japan
detect
use
elisa
secondari
antibodi
antimous
iga
individu
serum
sampl
week
level
antiphecov
mice
immun
five
vaccin
ip
ipv
ipv
ipv
significantli
differ
control
group
pb
p
unit
state
posit
depend
region
survey
convers
neuvonen
et
al
found
finnish
elit
breed
pig
herd
free
seroposit
anim
furthermor
pig
receiv
protect
antibodi
colostrum
howev
piglet
without
phecov
antibodi
especi
specificpathogenfre
spf
pig
breed
farm
sever
countri
includ
china
greater
risk
phecov
infect
moreov
recess
spread
phecov
viral
gene
may
mutat
reinforc
virul
anoth
potenti
threat
phecov
anim
infect
phecov
appear
wast
stunt
affect
perform
qualiti
meat
thu
potenti
hazard
diseas
pig
industri
ignor
current
report
phecov
vaccin
china
elsewher
although
sever
countri
use
subclin
infect
mean
prevent
subclin
infect
sow
expos
either
contact
sick
pig
spray
intramuscular
inject
weak
strain
phecov
sow
protect
piglet
colostrum
antibodi
howev
method
induc
immun
danger
sinc
phecov
variant
differ
level
virul
could
undergo
genet
recombin
increas
overal
virul
viru
therefor
develop
safe
highperform
vaccin
prevent
treatment
phecov
import
practic
signific
describ
construct
inactiv
phecov
dna
candid
vaccin
use
differ
immun
protocol
murin
model
immun
protocol
immun
mice
stimul
phecov
cona
od
splenocyt
prolifer
determin
compar
background
od
od
posit
control
od
valu
five
vaccin
group
ip
group
ipv
group
group
group
ipv
group
show
signific
differ
p
mice
immun
inactiv
phecov
plu
alum
ipv
group
induc
stronger
prolifer
respons
mice
immun
inactiv
phecov
ip
group
p
howev
od
valu
ipv
group
increas
slightli
compar
ipv
group
p
od
valu
show
obviou
differ
ipv
group
group
p
splenocyt
collect
immun
mice
analyz
use
flow
cytometri
percentag
cell
mice
immun
ipv
ip
ipv
ipv
significantli
higher
mice
immun
pb
control
p
b
cell
ratio
higher
mice
immun
vaccin
control
group
use
evalu
abil
vaccin
induc
serum
neutral
antibodi
cellular
immun
respons
order
defin
correl
immun
protect
phecov
found
vaccin
ipv
induc
level
serum
neutral
antibodi
much
higher
vaccin
group
level
neutral
antibodi
vn
titer
high
increas
time
immun
three
immun
mice
thu
addit
alum
ipv
prepar
found
increas
serum
vn
activ
significantli
aluminum
hydroxid
adjuv
still
adjuv
approv
fda
use
human
vaccin
mechan
action
appear
storag
effect
notabl
could
induc
vn
antibodi
booster
found
increas
level
antigen
present
vivo
combin
use
ipv
dna
vaccin
induc
even
higher
level
serum
neutral
antibodi
vn
titer
ipv
group
higher
ipv
group
thu
addit
alum
inactiv
phecov
combin
immun
increas
time
immun
anim
could
effect
stimul
humor
immun
respons
previou
studi
shown
protect
effect
dna
vaccin
depend
higher
dose
immun
booster
design
improv
antigen
express
level
could
induc
high
level
antibodi
respons
fulli
effect
immun
protect
studi
gene
phecov
subclon
vector
eukaryot
express
vector
approv
human
use
fda
construct
recombin
plasmid
use
phecov
dna
vaccin
mice
given
three
intramuscular
inject
ipv
alon
combin
immun
ipv
ipv
immun
result
induct
serum
neutral
antibodi
protect
efficaci
phecov
challeng
mice
receiv
full
biolog
protect
phecov
could
still
detect
rtpcr
ipv
group
result
subclass
serum
antibodi
analysi
show
ipv
mediat
primarili
immun
respons
wherea
mediat
respons
suggest
ipv
may
induc
predominantli
immun
respons
sinc
alum
known
select
stimul
type
immun
respons
addit
humor
immun
respons
also
demonstr
induct
tcell
immun
respons
studi
splenocyt
immun
mice
stimul
phecov
cona
spleen
lymphocyt
prolifer
conspicu
ipv
group
prolifer
rate
lower
combin
immun
group
ipv
ipv
group
indic
ipv
could
systemat
induc
suffici
cellular
immun
respons
follow
combin
immun
good
effect
lymphocyt
gener
divid
cytotox
tc
cell
suppressor
ts
cell
de
assess
product
cytokin
elicit
two
phecov
vaccin
candid
frequenc
cell
produc
singlecel
level
determin
use
elisa
kit
level
cytokin
produc
immun
mice
show
signific
differ
five
vaccin
group
ip
ipv
ipv
ipv
control
group
pb
p
ipv
group
produc
mainli
higher
level
group
p
howev
level
obvious
differ
ipv
group
p
layedtyp
hypersensit
cell
helperinduc
th
cell
distribut
th
cell
surfac
increas
number
memori
cell
respond
rapidli
upon
reexposur
pathogen
thu
play
vital
role
protect
viral
challeng
distribut
surfac
ts
tc
cell
follow
activ
antigenspecif
cell
abl
prolifer
quickli
differenti
potent
effector
cell
capabl
rapid
cytokin
product
cytolyt
kill
target
cell
use
flow
cytometri
determin
subset
specif
memori
tcell
respons
found
immun
mice
studi
percentag
activ
cell
significantli
increas
among
immun
group
except
control
group
wherea
ipv
group
highest
ratio
cell
among
immun
group
thu
combin
immun
ipv
success
induc
cellular
immun
although
either
ipv
alon
could
also
elicit
high
region
level
cell
spleen
lymphocyt
cytokin
gener
micromolecular
polypeptid
secret
immun
cell
play
import
role
regul
cell
function
respect
cell
growth
differenti
transmiss
inform
cell
immunolog
compet
cell
involv
specif
immun
respons
accordingli
express
differ
cytokin
divid
cell
cell
subset
major
cytokin
associ
cell
subset
other
main
role
cytokin
enhanc
tc
cellular
cytotox
cellmedi
immun
respons
cell
subset
secret
main
role
cytokin
promot
antibodi
product
mediat
humor
immun
respons
determin
frequenc
cell
produc
singlecel
level
use
elispot
assay
ipv
group
induc
mainli
higher
level
ip
group
indic
ipv
may
tend
select
tcell
subset
phenotyp
immun
combin
immun
ipv
ipv
induc
mainli
suggest
select
strong
cellular
immun
respons
may
play
import
role
stimul
immun
respons
interestingli
ipv
group
induc
high
level
may
produc
immun
respons
may
turn
elicit
phagocytemedi
defens
phecov
infect
import
viral
clearanc
current
dna
vaccin
less
abl
tradit
inactiv
vaccin
overcom
effect
matern
antibodi
induc
immun
respons
thu
birth
young
anim
matern
antibodi
level
decreas
enough
prevent
resist
viral
infect
immun
dna
vaccin
may
effect
prevent
measur
furthermor
humor
cellular
immun
respons
known
contribut
protect
coronaviru
infect
though
cell
may
also
play
role
exacerb
patholog
anim
coronaviru
infect
summari
report
first
sidebysid
descript
two
phecov
vaccin
evalu
abil
induc
immunogen
data
indic
ipv
effect
dna
vaccin
induc
humor
immun
respons
protect
phecov
howev
mice
vaccin
twice
dna
vaccin
boost
ipv
could
activ
b
cell
induc
specif
humor
cellular
immun
respons
good
efficaci
challeng
live
phecov
thu
combin
immun
dna
inactiv
vaccin
could
serv
candid
protocol
prevent
phecov
direct
comparison
phecov
vaccin
anim
model
determin
vaccin
strategi
effect
also
shorten
time
requir
best
vaccin
candid
progress
pigtest
phase
